The American Journal of Drug and Alcohol Abuse
August 22, 2025
P. Manza, Annabelle M. Belcher, Heather Fitzsimons et al.
ABSTRACT Background: Opioid use disorder (OUD) is a chronic relapsing condition with a high mortality rate. While medications such as methadone are valuable first-line therapies, retention is poor, with the highest dropout rates early in a treatment attempt. Poor outcomes are due in part to the very high rates of co-morbid depression in people with OUD, as depression can drive opioid use....
The American Journal of Drug and Alcohol Abuse
September 2, 2024
Ming-Chyi Huang, Li-Jung Chiang, Wan-Hsi Chien et al.
Background: Ketamine has emerged as a prominent substance of misuse. Leptin, an adipocyte-derived polypeptide hormone, has been implicated in the development of addiction. Sex-specific changes in leptin levels have been demonstrated following acute ketamine administration; the persistence of long-term ketamine use on leptin levels is uncertain.Objectives: To assess the sex-difference of leptin...
The American Journal of Drug and Alcohol Abuse
November 2, 2023
Fernando Mendive, Cecile Giovannetti, Sara García Arce
4 citations
Background: There exists an underexploited opportunity to develop innovative therapeutic approaches to SUDs based upon the complementarity between modern and traditional health systems.Objectives: Illustrate the feasibility and potentiality of such an approach through the comprehensive description of Takiwasi Center's treatment model and program, where health concepts and practices from...
The American Journal of Drug and Alcohol Abuse
September 3, 2023
Joseph J Palamar
29 citations
A drug concoction called tusi has emerged in Latin America and in Europe and is now beginning to acquire popularity in the United States. "Tusi" is a phonetic translation of "2C," a series of psychedelic phenethylamines. The concoction is also sometimes referred to as "pink cocaine" as it typically comes in the form of pink powder. However, despite its name, the concoction rarely contains 2C...
The American Journal of Drug and Alcohol Abuse
September 3, 2023
Alan Kooi Davis, Yitong Xin, Nathan D. Sepeda et al.
29 citations
Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in...
The American Journal of Drug and Alcohol Abuse
March 4, 2023
Nicole Ledwos, Aurelia I Andreiev, Tianna Costa et al.
NyQuil is an over-the-counter medication containing the pain reliever, acetaminophen; the antihistamine, doxylamine; and dextromethorphan (DXM), the antitussive medication. The Nyquil liquid formulation also contains alcohol, listed among the inactive ingredients. DXM has dependence-producing properties and addiction liability, especially in young people (1). Large doses (>1500 mg/day) can...
The American Journal of Drug and Alcohol Abuse
June 5, 2021
David J. Cox, Albert Garcia‐romeu, Matthew W. Johnson
29 citations
Background: Experiences with psychedelic drugs, such as psilocybin or lysergic acid diethylamide (LSD), are sometimes followed by changes in patterns of tobacco, opioid, and alcohol consumption. But, the specific characteristics of psychedelic experiences that lead to changes in drug consumption are unknown.Objective: Determine whether quantitative descriptions of psychedelic experiences...
The American Journal of Drug and Alcohol Abuse
March 4, 2019
Elias Dakwar
1 citation
This article refers to:5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
The American Journal of Drug and Alcohol Abuse
2019
Alan K. Davis, Sara So, Rafael Lancelotta et al.
141 citations
A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. We examined self-reported improvement in depression and anxiety among people who...
The American Journal of Drug and Alcohol Abuse
January 2, 2018
Deborah C. Mash
29 citations
Ibogaine is an indole alkaloid that comes from the root of the West African shrub Tabernanthe iboga. Ibogaine has been used for centuries in spiritual celebrations, coming of age rituals, and heali...
The American Journal of Drug and Alcohol Abuse
2018
Thomas Kingsley Brown, Kenneth Alper
156 citations
Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. To study outcomes following opioid detoxification with ibogaine. In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5...
The American Journal of Drug and Alcohol Abuse
2018
Geoffrey E Noller, Chris M Frampton, Berra Yazar-Klosinski
150 citations
The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine treatment for opioid dependence. This...
The American Journal of Drug and Alcohol Abuse
November 1, 2016
Joseph J Palamar, Patricia Acosta, Scott J Sherman et al.
73 citations
Novel psychoactive substances (NPSs) continue to emerge in the United States and worldwide. Few epidemiological studies have examined the prevalence and correlates of use. We examined the extent of NPS use in a high-risk population-attendees of electronic dance music (EDM) parties at nightclubs and festivals. We surveyed 682 adults (age 18-25) entering EDM events at nightclubs and festivals in...
The American Journal of Drug and Alcohol Abuse
August 24, 2016
Michael P. Bogenschutz
18 citations
In the current issue of the American Journal of Drug and Alcohol Abuse, Johnson et al. (1) provide long-term outcome data from a smoking cessation pilot study of a treatment model using 2–3 doses o...
The American Journal of Drug and Alcohol Abuse
July 21, 2016
Matthew W. Johnson, Albert Garcia‐romeu, Roland R. Griffiths
702 citations
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To...
The American Journal of Drug and Alcohol Abuse
August 22, 2013
Brittany Vasae Burdick, Bryon Adinoff
Current treatments for addiction are frequently ineffective. Hallucinogenic therapy has been indicated as helpful for a range of substance use disorders, yet this approach remains understudied and publicly unavailable. It is nonetheless a promising treatment, which has significant, long-term beneficial effects with single doses and a profile characterized by general safety, low toxicity, and...
The American Journal of Drug and Alcohol Abuse
2012
Brian E Perron, Brian K Ahmedani, Michael G. Vaughn et al.
36 citations
Salvia divinorum has known hallucinogenic effects and is legal in most parts of the United States. Given that this psychoactive substance has a potential of misuse and abuse, further data regarding the clinical and psychosocial factors associated with use are needed. To examine the clinical and psychosocial characteristics associated with use of salvia. The study uses data from the National...
The American Journal of Drug and Alcohol Abuse
2007
F. Gerard Moeller, Joel L. Steinberg, Scott D Lane et al.
39 citations
Diffusion Tensor Imaging (DTI) may provide information regarding effects of 3,4-methylenedioxymethamphetamine (MDMA) use on brain structure. Twelve MDMA users and 20 healthy controls underwent whole brain DTI data acquisition. Fractional anisotropy (FA), mean diffusivity (D(av)), and longitudinal (lambda(1)) and transverse (lambda(T)) diffusivities were compared between MDMA users and controls...
The American Journal of Drug and Alcohol Abuse
1993
Robert S. Gable
105 citations
A procedure is outlined for comparing dependence potential and acute toxicity across a broad range of abused psychoactive substances. Tentative results, based on an extensive literature review of 20 substances, suggested that the margin of safety ("therapeutic index") varied dramatically between substances. Intravenous heroin appeared to have the greatest risk of dependence and acute lethality;...
The American Journal of Drug and Alcohol Abuse
1992
John H. Krystal, Lawrence H. Price, Charles Opsahl et al.
171 citations
3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a selective serotonin (5-HT) neurotoxin in animals. There is now preliminary evidence in humans of 5-HT deficits associated with extensive use of MDMA. In order to begin to describe the cognitive and mood effects of chronic MDMA use, nine individuals with extensive MDMA use histories were studied. Despite the absence of memory deficits on...